Merck Serono puts its future in Quintiles' hands
This article was originally published in Scrip
Executive Summary
Continuing a trend for large pharma to entrust vast swathes of their clinical trials to a single CRO partner, Merck Serono has signed a new, five-year agreement with Quintiles to form a "single, well-aligned clinical development engine".